Highlights of the Chemotherapy Foundation Symposium XXVII: therapeutic options for breast cancer

Expert Review of Anticancer Therapy
Myra F Barginear, George Raptis

Abstract

The XXVII Annual Chemotherapy Foundation Symposium sponsored by The Mount Sinai School of Medicine is one of the leading forums for communication of important discoveries and new developments in cancer therapeutics. Here, we summarize and review the emerging advances in the treatment of breast cancer, which includes therapeutics in HER signaling, poly(ADP-ribose) polymerase inhibition, PI3K inhibitors and novel epithilones.

References

Oct 8, 1987·The New England Journal of Medicine·D J Slamon
Aug 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J S AbramsM A Friedman
Jul 6, 2007·The New England Journal of Medicine·Clifford A Hudis
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
May 30, 2008·Frontiers in Bioscience : a Journal and Virtual Library·Laura M Bender, Rita Nahta
May 13, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carolyn D SeibBrent T Shoji
Jun 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David J Gallagher, Nancy E Kemeny

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Related Papers

Science's STKE : Signal Transduction Knowledge Environment
Nancy R Gough
The Mount Sinai Journal of Medicine, New York
Allan P Reed
The Mount Sinai Journal of Medicine, New York
S H Barnett, A Stagnaro-Green
© 2021 Meta ULC. All rights reserved